<div id="readability-page-1"><div><p>Morgan Stanley issued a research report updating its risk-reward assessment on Shanghai Pharmaceuticals Holding (02607.HK)<span> </span><span> -0.100 (-0.843%)  </span> <span> Short selling $2.61M; Ratio 22.892%  </span> . Based on its 2025 results, the broker lowered its earnings forecasts for 2026 to 2030 by 2% to 3% to reflect a more conservative revenue outlook for the group.</p><p>M Stanley maintained an Overweight rating on the stock and reduced its target price from HKD16 to HKD15.8. It forecast the groups EPS to reach RMB1.46 in 2026, RMB1.61 in 2027 and RMB1.72 in 2028. (hc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-23 16:25.)</p></div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p></div>

601607

02607

159992

<p>Morgan Stanley has updated its risk-reward assessment on Shanghai Pharmaceuticals Holding, lowering its target price from HKD16 to HKD15.8 while maintaining an Overweight rating. The broker revised its earnings forecasts for 2026 to 2030 down by 2% to 3% due to a conservative revenue outlook. EPS is projected to reach RMB1.46 in 2026, RMB1.61 in 2027, and RMB1.72 in 2028.</p>

AASTOCKS News

Shanghai Pharma

SH PHARMA

Yinhua CSI Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

GF CSI All Share Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP CSI Pharmaceuticals ETF

Guotai SSE STAR Brand Name Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts Shanghai Pharmaceuticals Holding  TP to HKD15.8, Rating Overweight